Efficacy and Safety of Patupilone in Men (â‰¥18 Years) With Metastatic Hormone Refractory Prostate Cancer
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.
Metastatic Hormone Refractory Prostate Cancer
DRUG: Patupilone|DRUG: prednisone|DRUG: docetaxel
Antitumor response based on PSA decrease, Every 3 weeks
Measurable soft tissue response for both regimens, Every 6 weeks or every 12 weeks if patient has bone disease for bone scan
The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.